GAIA, Daiichi Sankyo Europe Partner to Launch Digital Therapeutic for Cardiovascular Care

German digital therapeutics company GAIA has entered an exclusive strategic partnership with Daiichi Sankyo Europe to commercialize a next-generation digital therapeutic aimed at improving cardiovascular care across Europe.
The collaboration focuses on lipodia, a digital therapeutic designed to support adults living with hypercholesterolemia, a major risk factor for cardiovascular disease. The solution combines evidence-based behavioral science with digital technology to encourage long-term lifestyle changes that can improve heart health.
Lipodia uses interactive digital tools and psychological techniques to help patients adopt healthier habits, including improved diet, physical activity, stress management, and sleep routines. The fully automated program adapts to individual patient needs and can be accessed on connected devices, allowing patients to use it remotely.
Under the agreement, Daiichi Sankyo Europe will receive exclusive commercialization rights for lipodia, initially in Germany, with potential expansion to other European markets. The partnership aims to complement traditional drug therapies by integrating digital therapeutics into routine cardiovascular care.
GAIA plans to seek reimbursement for lipodia through Germany’s DiGA digital health application pathway after results from a phase-3 randomized clinical trial become available. If approved, physicians would be able to prescribe the digital therapy, with reimbursement through statutory health insurance.
Cardiovascular diseases remain the leading cause of death in Europe, with thousands of deaths reported daily. Through this partnership, the companies aim to address the behavioral and lifestyle factors that contribute to cardiovascular risk and improve long-term patient outcomes through digital innovation.